Inspirna, Inc. Email Format

Biotechnology ResearchNew York, United States2-10 Employees

Inspirna, Inc. is a small, privately held clinical-stage biotechnology company based in New York City, New York, focused on discovering and developing novel cancer therapies that target pathways involved in cancers with high unmet clinical needs. Its lead candidate, ompenaclid (RGX-202), is an orally administered small molecule that blocks the CKB/SLC6A8 pathway, supporting ATP generation under tumor hypoxia, and is being evaluated in mid-stage trials for advanced or metastatic RAS-mutant colorectal cancer. Its second candidate, abequolixron (RGX-104), is an oral small molecule that activates LXR/APOE to inhibit angiogenesis and reduce tumor myeloid-derived suppressor cells, with Phase 1b/2 trials in combination regimens for lung cancer and endometrial cancer under a collaboration with Bristol Myers Squibb. Inspirna identifies novel cancer targets through RNA-DRIVEr, a microRNA-based discovery platform originally developed at The Rockefeller University and exclusively licensed to the company. The firm maintains externally focused collaborations, including a licensing agreement with Merck KGaA in January 2024. Its leadership combines scientific founders with an experienced board and management team.

Get verified Inspirna, Inc. emails free

Company overview Employee directory